MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ
12.83
-0.34
-2.58%
After Hours: 13.00 +0.17 +1.33% 18:54 01/27 EST
OPEN
13.11
PREV CLOSE
13.17
HIGH
13.21
LOW
12.79
VOLUME
1.78M
TURNOVER
0
52 WEEK HIGH
13.62
52 WEEK LOW
5.91
MARKET CAP
3.60B
P/E (TTM)
-14.0480
1D
5D
1M
3M
1Y
5Y
Insider Sell: Amicus Therapeutics
Insider Sell: Amicus Therapeutics
MT Newswires · 4d ago
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
Benzinga · 4d ago
Vir Biotechnology: High Potential Returns With High Volatility Risks
Seeking Alpha · 01/19 07:59
BTIG Maintains Buy on Amicus Therapeutics, Raises Price Target to $16
Benzinga · 01/18 13:38
BTIG Adjusts Price Target on Amicus Therapeutics to $16 From $14, Maintains Buy Rating
BTIG Adjusts Price Target on Amicus Therapeutics to $16 From $14, Maintains Buy Rating
MT Newswires · 01/18 10:49
Amicus: While AT-GAA For Pompe Faces Delay, Troubles Slowly Raise Their Heads
Seeking Alpha · 01/15 13:57
BRIEF-Amicus Therapeutics Reports Provides 2023 Strategic Outlook
Reuters · 01/09 12:43
Amicus Therapeutics Reports 2022 Preliminary Revenue Growth
Amicus Therapeutics Reports 2022 Preliminary Revenue Growth
MT Newswires · 01/09 07:50
More
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.